US phase III trial of nabiximols (Sativex) for spasticity due to multiple sclerosis
Phase of Trial: Phase III
Latest Information Update: 07 May 2014
At a glance
- Drugs Nabiximols (Primary)
- Indications Multiple sclerosis
- Focus Registrational; Therapeutic Use
- 07 May 2014 According to the GW Pharmaceuticals media release published on 7 May 2014, the US FDA granted Special Protocol Assessment.
- 15 Aug 2013 New trial record
- 14 Aug 2013 GW Pharmaceuticals has opened a Phase 3 IND application with the US FDA and this trial is expected to commence in 2014, according to a media release.